iRadimed/$IRMD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About iRadimed

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

Ticker

$IRMD
Sector
Primary listing

Employees

160

iRadimed Metrics

BasicAdvanced
$913M
44.58
$1.61
0.95
$0.66
0.95%

What the Analysts think about iRadimed

Analyst ratings (Buy, Hold, Sell) for iRadimed stock.

Bulls say / Bears say

Received FDA 510(k) clearance for the next-generation MRidium® 3870 IV Infusion Pump System, reinforcing iRadimed’s unique position as the sole global supplier of non-magnetic MRI infusion pumps and paving the way for a strategic Q4 2025 rollout and full commercial distribution in 2026 (Reuters).
Reported a sixteenth consecutive quarter of record revenue, with Q2 2025 sales of $20.4 million, up 14% year-over-year, driven by strong demand for its MRI-compatible IV pump and monitoring systems (AP).
Raised full‐year 2025 revenue guidance to $80.0 million–$82.5 million (up from $78.0 million–$82.0 million previously), reflecting management’s confidence in sustained demand and operational momentum (AP).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

iRadimed Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

iRadimed Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IRMD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs